Multidisciplinary therapy for metastatic liver cancer. With special reference to gastric and colorectal cancer patients with hepatic metastasis.

Abstract Background There have been controversial voices on if hepatitis B virus infection decreases the risk of colorectal liver metastases or not. This study aims to the find the association between HBV infection and postoperative survival of colorectal cancer and the risk of liver metastases in colorectal cancer patients. Methods Patients who underwent curative surgical resection for colorectal cancer between January 2011 and December 2012 were included. Patients were grouped according to anti-HBc. Differences in overall survival, time to progress, and hepatic metastasis-free survival between groups and significant predictors were analyzed. Results Three hundred twenty-seven colorectal cancer patients were comprised of 202 anti-HBc negative cases and 125 anti-HBc positive cases, and anti-HBc positive cases were further divided into high-titer anti-HBc group (39) and low-titer anti-HBc group (86). The high-titer anti-HBc group had significantly worse overall survival (5-Yr, 65.45% vs. 80.06%; P < .001), time to progress (5-Yr, 44.26% vs. 84.73%; P < .001), and hepatic metastasis-free survival (5-Yr, 82.44% vs. 94.58%; P = .029) than the low-titer group. Multivariate model showed anti-HBc ≥ 8.8 S/CO was correlated with poor overall survival (HR, 3.510; 95% CI, 1.718–7.17; P < .001), time to progress (HR, 5.747; 95% CI, 2.789–11.842; P < .001), and hepatic metastasis-free survival (HR, 3.754; 95% CI, 1.054–13.369; P = .041) in the anti-HBc positive cases. Conclusions Higher titer anti-HBc predicts a potential higher risk of liver metastases and a worse survival in anti-HBc positive colorectal cancer patients.

Download Full-text

Predicting biomarkers of hepatic metastasis in Chinese colorectal cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.e15545 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. e15545-e15545

Author(s):

Honghua Peng ◽

Tianhao Mu ◽

Yaping Sheng ◽

Yingmei Li ◽

Peiguo Cao

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Cancer Patients ◽

Hepatic Metastasis ◽

Primary Tumor ◽

Potential Candidate ◽

Poor Overall Survival ◽

Primary Tumors ◽

Distant Spread ◽

Colorectal Cancer Patients

e15545 Background: Hepatic metastasis is the most common site of distant spread from colorectal cancer. About 15-25% patients with colorectal cancer harbors hepatic metastasis. The molecular mechanism and predicting biomarkers in colorectal cancer are still not fully understood. Methods: 57 Chinese colorectal cancer patients were enrolled in a cohort study. Samples of primary tumor were collected in these patients and underwent whole exome sequencing. Mutation profiles of primary tumors between the patients with metastasis and those without metastasis were analyzed and compared. Results: In the cohort, 54.4% (31/57) patients presented hepatic metastasis at the time of diagnosis, while 45.6% (26/57) did not. The patients were divided into 2 groups—with hepatic metastasis and without hepatic metastasis. The mutation landscape of primary tumor indicated that the Top 3 most frequently mutated genes of both groups were the same and presented mutated TP53, APC, and KRAS. 2. Interestingly, compared with the patients without hepatic metastasis, the patients with hepatic metastasis presented a higher frequency of mutated TCF7L2 (35.5% vs 3.85%) and TRIM77 (16.1% vs 0%). Moreover, in the patients with hepatic metastasis, the patients with TRIM77 mutation in primary tumor showed a worse overall survival (p < 0.0001). Conclusions: TCF7L2 and TRIM77 may be identified as potential candidate predicting biomarkers for hepatic metastasis in colorectal patients. In addition, mutated TRIM 77 predicted a poor overall survival in hepatic metastasis from colorectal cancer.

Download Full-text

Cyclooxygenase (COX)-1, Cyclooxygenase (COX)-2 and E-cadherin Expression in Colorectal Cancer Patients with Hepatic Metastasis

Journal of the Korean Surgical Society ◽

10.4174/jkss.2010.78.3.177 ◽

2010 ◽

Vol 78 (3) ◽

pp. 177

Author(s):

Sun Hyung Joo ◽

Bum Soo Kim ◽

Sung Il Choi ◽

Jeong Yoon Song ◽

Kil Yeon Lee ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Hepatic Metastasis ◽

Cox 2 ◽

Colorectal Cancer Patients ◽

Cox 1 ◽

E Cadherin

Download Full-text

Silencing phospholipid scramblase 1 expression by RNA interference in colorectal cancer and metastatic liver cancer

Hepatobiliary & Pancreatic Diseases International ◽

10.1016/s1499-3872(12)60197-0 ◽

2012 ◽

Vol 11 (4) ◽

pp. 393-400 ◽

Cited By ~ 15

Author(s):

Wei Cui ◽

Shi-Yong Li ◽

Jun-Feng Du ◽

Zi-Man Zhu ◽

Ping An

Keyword(s):

Colorectal Cancer ◽

Rna Interference ◽

Liver Cancer ◽

Metastatic Liver Cancer ◽

Phospholipid Scramblase ◽

Phospholipid Scramblase 1 ◽

Metastatic Liver

Download Full-text

High prevalence of diabetes mellitus and impaired glucose tolerance in liver cancer patients: A hospital based study of 4610 patients with benign tumors or specific cancers

F1000Research ◽

10.12688/f1000research.8457.1 ◽

2016 ◽

Vol 5 ◽

pp. 1397 ◽

Cited By ~ 1

Author(s):

Chen Roujun ◽

Yi Yanhua ◽

Li Bixun

Keyword(s):

Colorectal Cancer ◽

Liver Cancer ◽

Cancer Patients ◽

Benign Tumor ◽

Nasopharyngeal Cancer ◽

Benign Tumors ◽

Tumor Patients ◽

High Prevalence ◽

Colorectal Cancer Patients ◽

Prevalence Of Diabetes Mellitus

Objective: The prevalence of diabetes mellitus (DM), impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) were hypothesised to be different among different tumor patients. This study aimed to study the association between the prevalence of DM, IGT and IFG and liver cancer, colorectal cancer, breast cancer, cervical cancer, nasopharyngeal cancer and benign tumor. Methods: A hospital based retrospective study was conducted on 4610 patients admitted to the Internal Medical Department of the Affiliated Tumor Hospital of Guangxi Medical University, China. Logistic regression was used to examine the association between gender, age group, ethnicity , cancer types or benign tumors and prevalence of DM, IFG, IGT. Results: Among 4610 patients, there were 1000 liver cancer patients, 373 breast cancer patients, 415 nasopharyngeal cancer patients, 230 cervical cancer patients, 405 colorectal cancer patients, and 2187 benign tumor patients. The prevalence of DM and IGT in liver cancer patients was 14.7% and 22.1%, respectively. The prevalence of DM and IGT was 13.8% and 20%, respectively, in colorectal cancer patients, significantly higher than that of benign cancers. After adjusting for gender, age group, and ethnicity, the prevalence of DM and IGT in liver cancers patients was 1.29 times (CI :1.12-1.66) and 1.49 times (CI :1.20-1.86) higher than that of benign tumors, respectively. Conclusion: There was a high prevalence of DM and IGT in liver cancer patients.

Download Full-text

Higher Titer Hepatitis B Core Antibody Predicts a Higher Risk of Liver Metastasis and Worse Survival in Patients With Colorectal Cancer

10.21203/rs.3.rs-335277/v1 ◽

2021 ◽

Author(s):

Ziyao Li ◽

Shaofei Li ◽

Hangbo Tao ◽

Yixiang Zhan ◽

Kemin Ni ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Liver Metastasis ◽

Cancer Patients ◽

Hepatic Metastasis ◽

High Titer ◽

Poor Overall Survival ◽

Free Survival ◽

Titer Group ◽

Colorectal Cancer Patients

Abstract Purpose: This study aims to the find the association between HBV infection and postoperative survival and the risk of liver metastasis in colorectal cancer patients.Methods: Patients who underwent curative surgical resection for colorectal cancer (CRC) between January 2011 and December 2012 were included. Patients were grouped according to anti-HBc. Differences in overall survival (OS), time to progress (TTP) and hepatic metastasis-free survival (HMFS) between groups and significant predictors were analyzed.Results: 327 colorectal cancer patients are comprised of 202 anti-HBc negative cases and 125 anti-HBc positive cases, and anti-HBc positive cases are further divided into high-titer anti-HBc group (39) and low-titer anti-HBc group (86). High-titer anti-HBc group had significantly worse overall survival (5-Yr, 65.45% vs. 80.06%; P < .001), time to progress (5-Yr, 44.26% vs. 84.73%; P < .001) and hepatic metastasis-free survival (5-Yr, 82.44% vs. 94.58%; P = .029) than low-titer group. Multivariate model showed anti-HBc ≥ 8.8 S/CO was correlated with poor overall survival (HR, 3.510; 95% CI, 1.718-7.17; P < .001), time to progress (HR, 5.747; 95% CI, 2.789-11.842; P < .001) and hepatic metastasis-free survival (HR, 3.754; 95% CI, 1.054-13.369; P = .041) in the anti-HBc positive cases.Conclusion: Higher titer anti-HBc predicts a higher risk of liver metastasis and a worse survival in anti-HBc positive colorectal cancer patients.

Download Full-text